- Home
- SOPH vs OCGN Comparison
SOPH vs OCGN Comparison
Compare SOPH & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOPH
- OCGN
- Stock Information
- Founded
- SOPH 2011
- OCGN 2013
- Country
- SOPH Switzerland
- OCGN United States
- Employees
- SOPH N/A
- OCGN N/A
- Industry
- SOPH Biotechnology: Biological Products (No Diagnostic Substances)
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SOPH Health Care
- OCGN Health Care
- Exchange
- SOPH Nasdaq
- OCGN Nasdaq
- Market Cap
- SOPH 219.8M
- OCGN 283.3M
- IPO Year
- SOPH 2021
- OCGN N/A
- Fundamental
- Price
- SOPH $3.46
- OCGN $1.11
- Analyst Decision
- SOPH Buy
- OCGN Strong Buy
- Analyst Count
- SOPH 1
- OCGN 3
- Target Price
- SOPH $7.00
- OCGN $6.00
- AVG Volume (30 Days)
- SOPH 152.3K
- OCGN 7.9M
- Earning Date
- SOPH 08-05-2025
- OCGN 08-07-2025
- Dividend Yield
- SOPH N/A
- OCGN N/A
- EPS Growth
- SOPH N/A
- OCGN N/A
- EPS
- SOPH N/A
- OCGN N/A
- Revenue
- SOPH $67,173,000.00
- OCGN $4,522,000.00
- Revenue This Year
- SOPH $16.07
- OCGN N/A
- Revenue Next Year
- SOPH $22.94
- OCGN N/A
- P/E Ratio
- SOPH N/A
- OCGN N/A
- Revenue Growth
- SOPH 4.66
- OCGN N/A
- 52 Week Low
- SOPH $2.58
- OCGN $0.52
- 52 Week High
- SOPH $4.92
- OCGN $1.98
- Technical
- Relative Strength Index (RSI)
- SOPH 58.47
- OCGN 60.16
- Support Level
- SOPH $2.81
- OCGN $0.91
- Resistance Level
- SOPH $3.79
- OCGN $1.19
- Average True Range (ATR)
- SOPH 0.27
- OCGN 0.08
- MACD
- SOPH 0.05
- OCGN 0.01
- Stochastic Oscillator
- SOPH 66.33
- OCGN 72.13
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").